Study of bortezomib, pomalidomide, and dexamethasone for AL amyloidosis
Treatments studied
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have AL amyloidosis confirmed by a biopsy and special tests.
- You are 18 years or older.
- You can be either newly diagnosed or have received treatment before.
- Your disease must be measurable by high levels of certain proteins in your blood or urine.
- You must have symptoms from organ involvement, such as heart, kidney, or nerve problems.
- Your blood counts and kidney function need to meet minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (SCTC21C) combined with three standard chemotherapy medicines for people who have just been diagnosed with AL amyloidosis. The goal is to see if adding the new drug helps reduce the abnormal protein deposits better than the standard treatment alone.
This trial tests a combination of two targeted drugs for people newly diagnosed with AL amyloidosis. You may qualify if you have a specific genetic marker (t(11;14)) and your organs are working well enough.
This study tests a new combination of medicines (daratumumab, bortezomib, and dexamethasone) as the first treatment for people with a specific type of amyloidosis (AL amyloidosis). It aims to see if this combination works better than standard care.
This trial tests a new drug combination for people with a specific type of AL amyloidosis (light chain amyloidosis) that has a genetic marker called t(11;14). The treatment includes Sonrotoclax (a targeted therapy) plus steroids, and possibly another drug called daratumumab, to see if it can help control the disease.
This trial is for people with AL amyloidosis who are being treated with daratumumab, bortezomib, and dexamethasone. It looks at how quickly a certain blood protein (called dFLC) drops after treatment starts and whether that predicts a complete remission.
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
Hear when a new Systemic Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.